Literature DB >> 1904083

Defective HLA DRA X box binding in the class II transactive transcription factor mutant 6.1.6 and in cell lines from class II immunodeficient patients.

E Stimac1, S Urieli-Shoval, S Kempin, D Pious.   

Abstract

6.1.6 is one of several immunoselected mutants from EBV-transformed human B cell lines that have undergone coordinate loss of expression of all their HLA class II genes. Similar defects have been found in cells from some patients with class II immunodeficiencies. Previous studies have suggested that the defects in 6.1.6 and in the other class II regulatory mutants are in transactive factors required for class II transcription. The defective factors, however, have not been identified. Here we present two lines of evidence that serve to localize the site of action of the factor that is defective in 6.1.6. First, transfected indicator genes linked to HLA DRA promoter fragments that include the conserved X box region are transiently expressed at greatly reduced levels in 6.1.6, compared with the progenitor cell line T5-1. Second, a DNA-protein complex, termed X-A, formed by nuclear extracts from T5-1 with DRA sequences containing the X box and a few bases 5' and 3' to it, is missing with extracts from 6.1.6. Extracts from some but not all patients with class II-negative immunodeficiency also fail to form X-A, whereas extracts from class II-negative mutants derived from the Burkitt's line Raji do form an apparently normal X-A complex. The X-A complex contains proteins of approximately 22, 32, 82, and 92 kDa that can be cross-linked to a 5-bromodeoxyuridine-substituted X box probe by UV light. A defect in an X box-binding protein, or in a factor required for its binding, is a likely cause for the loss of transcription of the class II genes in 6.1.6.

Entities:  

Mesh:

Substances:

Year:  1991        PMID: 1904083

Source DB:  PubMed          Journal:  J Immunol        ISSN: 0022-1767            Impact factor:   5.422


  11 in total

1.  Associations and interactions between bare lymphocyte syndrome factors.

Authors:  A M DeSandro; U M Nagarajan; J M Boss
Journal:  Mol Cell Biol       Date:  2000-09       Impact factor: 4.272

2.  The DNA-binding defect observed in major histocompatibility complex class II regulatory mutants concerns only one member of a family of complexes binding to the X boxes of class II promoters.

Authors:  C Herrero Sanchez; W Reith; P Silacci; B Mach
Journal:  Mol Cell Biol       Date:  1992-09       Impact factor: 4.272

3.  Deficient antigen-presenting cell function in multiple genetic complementation groups of type II bare lymphocyte syndrome.

Authors:  S Kovats; G T Nepom; M Coleman; B Nepom; W W Kwok; J S Blum
Journal:  J Clin Invest       Date:  1995-07       Impact factor: 14.808

4.  Definition of a novel complementation group in MHC class II deficiency.

Authors:  A Peijnenburg; B Godthelp; A van Boxel-Dezaire; P J van den Elsen
Journal:  Immunogenetics       Date:  1995       Impact factor: 2.846

5.  Reversion of a transcriptionally defective MHC class II-negative human B-cell mutant.

Authors:  M N Ombra; C Perfetto; M Autiero; A M Anzisi; R Pasquinelli; A Maffei; G Del Pozzo; J Guardiola
Journal:  Nucleic Acids Res       Date:  1993-02-11       Impact factor: 16.971

6.  Function of major histocompatibility complex class II promoters requires cooperative binding between factors RFX and NF-Y.

Authors:  W Reith; C A Siegrist; B Durand; E Barras; B Mach
Journal:  Proc Natl Acad Sci U S A       Date:  1994-01-18       Impact factor: 11.205

7.  RFXAP, a novel subunit of the RFX DNA binding complex is mutated in MHC class II deficiency.

Authors:  B Durand; P Sperisen; P Emery; E Barras; M Zufferey; B Mach; W Reith
Journal:  EMBO J       Date:  1997-03-03       Impact factor: 11.598

8.  The MHC class II transactivator (CIITA) requires conserved leucine charged domains for interactions with the conserved W box promoter element.

Authors:  J A Brown; E M Rogers; J M Boss
Journal:  Nucleic Acids Res       Date:  1998-09-15       Impact factor: 16.971

9.  Functional complementation of major histocompatibility complex class II regulatory mutants by the purified X-box-binding protein RFX.

Authors:  B Durand; M Kobr; W Reith; B Mach
Journal:  Mol Cell Biol       Date:  1994-10       Impact factor: 4.272

10.  Molecular characterization of major histocompatibility complex class II gene expression and demonstration of antigen-specific T cell response indicate a new phenotype in class II-deficient patients.

Authors:  I Hauber; H Gulle; H M Wolf; M Maris; H Eggenbauer; M M Eibl
Journal:  J Exp Med       Date:  1995-04-01       Impact factor: 14.307

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.